Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Proline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS2 | P35228 | 2/20 | 0.45 |
| ▸ | NOS3 | P29474 | 1/20 | 0.45 |
| ▸ | NOS1 | P29475 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | GLI1 | P08151 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | DPP4 | P27487 | 2/20 | 0.41 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.41 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.41 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.40 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.40 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.40 |
| ▸ | PRCP | P42785 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Proline SCHEMBL6547534 | 1.00 | NOS2 (0.45) | NOS2NOS3NOS1MEN1KMT2A | |
| Proline SCHEMBL302681 | 1.00 | NOS2 (0.45) | NOS2NOS3NOS1MEN1KMT2A | |
| Proline SCHEMBL419844 | 1.00 | NOS2 (0.45) | NOS2NOS3NOS1MEN1KMT2A | |
| Proline SCHEMBL3097543 | 1.00 | NOS2 (0.45) | NOS2NOS3NOS1MEN1KMT2A | |
| Proline SCHEMBL418934 | 1.00 | NOS2 (0.45) | NOS2NOS3NOS1MEN1KMT2A | |
| Proline SCHEMBL1429909 | 1.00 | NOS2 (0.45) | NOS2NOS3NOS1MEN1KMT2A | |
| Proline SCHEMBL302680 | 1.00 | NOS2 (0.45) | NOS2NOS3NOS1MEN1KMT2A | |
| D-Proline SCHEMBL18493080 | 1.00 | NOS2 (0.45) | NOS2NOS3NOS1MEN1KMT2A | |
| Proline SCHEMBL1675389 | 1.00 | NOS2 (0.45) | NOS2NOS3NOS1MEN1KMT2A | |
| Proline SCHEMBL1895918 | 1.00 | NOS2 (0.45) | NOS2NOS3NOS1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 90 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11007247-B2 | Compositions and methods for delivery of bioencapsulated proteins across blood-brain and retinal barriers | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2021-05-18 | — | — | US | claimed |
| US-20120269842-A1 | ENTEROTOXIGENIC E. COLI FUSION PROTEIN VACCINES | SOUTH DAKOTA STATE UNIVERSITY (US) | 2012-10-25 | — | — | US | claimed |
| EP-2485752-A2 | ENTEROTOXIGENIC E. COLI FUSION PROTEIN VACCINES | South Dakota State University (US) | 2012-08-15 | — | — | EP | claimed |
| WO-2011044499-A2 | ENTEROTOXIGENIC E. COLI FUSION PROTEIN VACCINES | SOUTH DAKOTA STATE UNIVERSITY (US) | 2011-04-14 | — | — | WO | claimed |
| CN-100450551-C | Recombinated adeno-associated virus genes vaccine for prevention and cure of Alzheimer disease and use thereof | INST OF BASIC MEDICINE CHINESE (CN) | 2009-01-14 | — | — | CN | claimed |
| US-20060122368-A1 | Antigen delivery platform | THE GOVERNMENT OF THE U.S.A. AS REPRESENTED BY THE SECRETARY OF THE DEPT. OF HEALTH & HUMAN SERVICES | 2006-06-08 | — | — | US | claimed |
| CN-1504240-A | Recombinated adeno-associated virus genes vaccine for prevention and cure of Alzheimer disease and use thereof | �й�ҽѧ��ѧԺ����ҽѧ�о��� | 2004-06-16 | — | — | CN | claimed |
| CN-111333733-B | Fusion protein capable of self-assembling into protein nanoparticles and application thereof | 中国人民解放军军事科学院军事医学研究院 | 2022-05-03 | — | — | CN | disclosed |
| US-11007247-B2 | Compositions and methods for delivery of bioencapsulated proteins across blood-brain and retinal barriers | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA (US) | 2021-05-18 | — | — | US | disclosed |
| CN-112423774-A | Therapeutic compositions and methods of use for treating mild cognitive impairment, depression and psychological disorders | L·H·L·特兰 | 2021-02-26 | — | — | CN | disclosed |
| EP-3763381-A1 | COMPOSITIONS FOR SUPPRESSION OF INHIBITOR FORMATION AGAINST FACTOR VIII IN HEMOPHILIA A PATIENTS | The Trustees Of The University Of Pennsylvania (US) | 2021-01-13 | — | — | EP | disclosed |
| US-20200270313-A1 | COMPOSITIONS AND METHODS FOR SUPPRESSION OF INHIBITOR FORMATION AGAINST COAGULATION FACTORS IN HEMOPHILIA PATIENTS | UNIV PENNSYLVANIA (US) | 2020-08-27 | — | — | US | disclosed |
| EP-3068869-B1 | COMPOSITIONS FOR SUPPRESSION OF INHIBITOR FORMATION AGAINST FACTOR VIII IN HEMOPHILIA A PATIENTS | UNIV PENNSYLVANIA (US) | 2020-07-22 | — | — | EP | disclosed |
| US-20060013831-A1 | Composition and method for enhancing immune response | ARIZONA BOARD OF REGENTS, ACTING FOR AND ON BEHALF OF ARIZONA STATE UNIVERSITY | 2006-01-19 | — | — | US | disclosed |
| EP-1456390-A4 | EXPRESSION OF PROTECTIVE ANTIGENS IN TRANSGENIC CHLOROPLASTS AND THE PRODUCTION OF IMPROVED VACCINES | UNIV CENTRAL FLORIDA (US) | 2005-12-21 | — | — | EP | disclosed |
| US-20050108792-A1 | Plastid transformation vector comprising anthrax protective antigen for use in generation of edible vaccines for conferring immunity to mammal against bacillus anthracis | THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA | 2005-05-19 | — | — | US | disclosed |
| EP-1456390-A2 | EXPRESSION OF PROTECTIVE ANTIGENS IN TRANSGENIC CHLOROPLASTS AND THE PRODUCTION OF IMPROVED VACCINES | University of Central Florida (US) | 2004-09-15 | — | — | EP | disclosed |
| CN-1504240-A | Recombinated adeno-associated virus genes vaccine for prevention and cure of Alzheimer disease and use thereof | �й�ҽѧ��ѧԺ����ҽѧ�о��� | 2004-06-16 | — | — | CN | disclosed |
| WO-2003075849-A2 | COMPOSITION AND METHOD FOR ENHANCING IMMUNE RESPONSE | ARIZONA BOARD OF REGENTS (US) | 2003-09-18 | — | — | WO | disclosed |
| WO-2003057834-A2 | EXPRESSION OF PROTECTIVE ANTIGENS IN TRANSGENIC CHLOROPLASTS AND THE PRODUCTION OF IMPROVED VACCINES | UNIVERSITY OF CENTRAL FLORIDA (US) | 2003-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120269842-A1 | ENTEROTOXIGENIC E. COLI FUSION PROTEIN VACCINES | TIAL1, RPS27A, ELL | NOS2 1378/4885NOS3 1717/4885NOS1 2063/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.